Skip to main content
  • Poster presentation
  • Open access
  • Published:

Is there concordance between LV fibrosis and RV fibrosis in patients with hypertrophic cardiomyopathy; should there be?


CMR has become the leading modality to define the clinical impact of hypertrophic cardiomyopathy (HCM) providing complete coverage of both ventricles with high spatial resolution. Late gadolinium enhancement (LGE) accurately identifies regions of myocardial fibrosis. Via CMR, innumerable studies have established that LVH and LGE are the predominant phenotypic expressions of HCM. It is well known that myocardial fibrosis can occur in patients with HCM and is independently linked to a poorer prognosis than those without fibrosis by CMR.


A retrospective review of all patients referred for HCM who underwent CMR was performed. SSFP/LGE techniques was used to diagnose patients with HCM, using gadolinium administration (0.15 mmol/kg, MultiHance, Bracco, Princeton-NJ), appropriate CMR phenotype, as well as clinical confirmation. Post-injection (10 minutes) LGE images were obtained using manual T1-weighted, IR-preparations. Regions of myocardium with LGE signals were visually designated as fibrotic. LV/RV mass indices (LVMI/RVMI) and ejection fractions were calculated. Fibrosis was semi-quantitatively assessed in both ventricles.


Via 72 patients referred for HCM from 2007-2013, 47(65%) were CMR and clinically confirmed to be HCM. The mean LVMI was 108 ± 44 g/m2 while the mean RVMI was 30 ± 21 g/m2. All patients met formal LVH criteria while 34/47 (72%) met RVH criteria. As well, 34/47(72%) had evidence of LV fibrosis while 24/47 (51%) had evidence for RV fibrosis. Only 2 patients with RV fibrosis had absent LV fibrosis. Of the RVH positive patients, 26/34(76%) patients were LV LGE positive and 18/34 (52%) were RV LGE positive.


The high frequency of RVH and RV fibrosis in the setting of HCM is surprising in that this phenomenon is rarely described. However, given the genetic abnormalities, there is no reason to expect the phenotypic expression should be limited to the LV. Interestingly, as for the LV, the presence or absence of RV fibrosis had little predictive power towards the systolic function. HCM effects both the LV and the RV.



Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Cite this article

Amin, N.N., Grant, S., Yamrozik, J.A. et al. Is there concordance between LV fibrosis and RV fibrosis in patients with hypertrophic cardiomyopathy; should there be?. J Cardiovasc Magn Reson 16 (Suppl 1), P313 (2014).

Download citation

  • Published:

  • DOI: